New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia

Basel, 08 December 2019 New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia At four-year follow-up of the MURANO study, Venclexta/Venclyxto plus... Read more

Fujifilm Establishes the Bio Science & Engineering Laboratories U.S.A. to Start Full-scale Translational Research for Biotherapeutics in the United States

Fujifilm Establishes the Bio Science & Engineering Laboratories U.S.A. to Start Full-scale Translational Research for Biotherapeutics in the United States – Fujifilm Cellular Dynamics Usage of Cookies: Cookies are important to the proper functioning of this site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to... Read more

Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology

Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology Comprehensive myeloid assay available in 2020 to run on the Ion Torrent Genexus System CARLSBAD, Calif., Dec. 5, 2019 /PRNewswire/ — Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a... Read more

Agilent Companion Diagnostic Expands CE-IVD mark in Europe to include Head and Neck Squamous Cell Carcinoma (HNSCC)

Agilent Companion Diagnostic Expands CE-IVD mark in Europe to include Head and Neck Squamous Cell Carcinoma (HNSCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) in Europe SANTA CLARA, Calif., November 22, 2019 Agilent Technologies, Inc. (NYSE: A) today announced that its PD-L1... Read more

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 22 November 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more